CERO Therapeutics (CERO) grants director Shami Patel options on 690,900 shares

Rhea-AI Filing Summary

CERO Therapeutics Holdings, Inc. reported that director Shami Patel received a stock option grant. On January 7, 2026, Patel was awarded an option to buy 690,900 shares of CERO common stock at an exercise price of $0.055 per share. The option is first exercisable on January 7, 2026 and expires on January 6, 2036. After this grant, Patel beneficially owns stock options covering 690,900 shares, held as a direct ownership position.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Patel Shami

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	690,900	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 690,900 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Shami

(Last) (First) (Middle)

CERO THERAPEUTICS HOLDINGS, INC.

201 HASKINS WAY, SUITE 230

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CERO THERAPEUTICS HOLDINGS, INC. [ CERO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.055	01/07/2026		A		690,900		01/07/2026	01/06/2036	Common Stock	690,900	$0.00	690,900	D

Explanation of Responses:

	/s/ Andrew Kucharchuk, Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CERO (CERO) report in this Form 4?

CERO reported that director Shami Patel was granted a stock option covering 690,900 shares of common stock on January 7, 2026.

What is the exercise price of the stock options granted to Shami Patel at CERO?

The stock option granted to Shami Patel has an exercise price of $0.055 per share of CERO common stock.

When do the new CERO stock options granted to director Shami Patel expire?

The stock options granted on January 7, 2026 expire on January 6, 2036, giving a ten-year term from the grant date.

How many CERO derivative securities does Shami Patel own after this transaction?

Following this grant, Shami Patel beneficially owns stock options covering 690,900 shares of CERO common stock on a direct basis.

What does transaction code "A" mean in the CERO Form 4 for Shami Patel?

In this context, transaction code "A" indicates an award or grant of derivative securities, here a stock option for 690,900 shares.

Is the stock option reported by CERO held directly or indirectly by Shami Patel?

The Form 4 indicates the stock option is held with direct (D) ownership by Shami Patel, with no indirect ownership relationship noted.